Business Briefs: AstraZeneca, Amgen, BMS and Merck
April 18, 2013
3:21 pm
AstraZeneca cuts a deal with OCB to test unnamed cancer drug; an Enbrel biosimilar launches in India; BMS and Santaris seal an mRNA tech deal; Merck expands its China presence; Alzheimer’s advocacy group parents a spin-off.